dr. morton seems like a nice guy. to get through this, baby. we are going to make it like it was. have been a huge star in your native sweden. everybody is predicting this is going to put you in the same frame stateside. doesn't feel that way to you? >> i feel incredibly blessed to get work with people like sam jackson and michael keaton, so for me it is a dream come true regardless. tavis: i read an interview you did the other day, and i was fascinated by a particular line i want to explore, but the article didn't give space to do this. that is this notion that putting on this sued for robocop you thought was going to be heavy and tiring, and it may have been all that, but when you put the suit on, wearing the suit day in day out spoke about the humanity of the character. what do you mean by that? >> it was more the contrast of emotions the character was going through. i didn't expect to find that from a suit. i put the suit on. it was uncomfortable and made me feel like a bad askss, but it also revealed some of the vulnerability the character was going through. i'm not wearing a

dr. throck morton, while the report be submitted no later than december 31, 2013, f.d.a.'s first annual shortages report was submitted to the committee on february 5. and with data from only the first three quarters of 2013. you notice in your testimony that 170 new shortages were prevented in 2013. this is up from 140 in the report f.d.a. submitted to the congress. i assume that means that f.d.a. claims to have prevented 30 shortages in the fort quarter of the year, is that correct? >> we do have our full year data available now and we'll be happy to share that with you, mr. chairman. >> let's use that smaller sample size for sake of discussion. it will be helpful to have more detailed examples of how f.d.a. prevented these shortages. what specific actions did the agency take? which drug products would currently be in shortage if not >> i can get you some specific information but i can give you some general examples if that would be helpful. one issue is something called regulatory flexibility. these are places where we either expedited additional actions that would other

dr. throck morton, while the report be submitted no later than december 31, 2013, f.d.a.'s first annual shortages report was submitted to the committee on february 5. and with data from only the first three quarters of 2013. you notice in your testimony that 170 new shortages were prevented in 2013. this is up from 140 in the report f.d.a. submitted to the congress. i assume that means that f.d.a. claims to have prevented 30 shortages in the fort quarter of the year, is that correct? >> we do have our full year data available now and we'll be happy to share that with you, mr. chairman. >> let's use that smaller sample size for sake of discussion. it will be helpful to have more detailed examples of how f.d.a. prevented these shortages. what specific actions did the agency take? which drug products would currently be in shortage if not for the agency's actions? >> i can get you some spiff information but i can -- specific information but i can give you some general examples if that would be helpful. one issue is something called regulatory flexibility. these are places wher